Complementary Medications (Statins, Nicergoline, Naftidrofuryl) in Dementia

Yaman, Aylin; Yaman, Hakan

doi:10.1007/978-3-319-56015-1_422-1

Aylin Yaman⁶ &
Hakan Yaman⁷

51 Accesses
1 Citations

Abstract

The demographic changes and aging of the population increase the prevalence of cognitive decline and dementia. Every country is affected by this phenomenon, and especially developing countries suffer from this condition, because of lack of appropriate caring infrastructure. In this review, preventive and symptomatic effects of some complementary medications in dementia are investigated. The focus is on agents like statins, nicergoline, and naftidrofuryl. Statins seem to prevent cognitive disorders by their beneficial effects against atherosclerosis, oxidation, inflammation, and amyloidogenicity and by enhancing neurogenesis. But some controversy exists concerning the utilization of statins in midlife for prevention of dementia and effects on mild cognitive impairment (MCI), vascular dementia (VaD), and Alzheimer’s disease (AD). Effective management of hypertension seems to prevent VaD and AD and might be beneficial to MCI. Nicergoline increases acetylcholine, noradrenaline, and dopamine levels and the regional blood flow in the brain. Some positive effects on cognition and behavior are observed. But further studies seem to be warranted for their safe and effective utilization. Other agents (i.e., nonsteroidal anti-inflammatory drugs, rosiglitazone, estrogen hormone, ginkgo biloba, antihypertensives), which were not subject of this review, but who were mentioned in the literature, lack studies showing significant effects on dementia.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

Adhyaru BB, Jacobson TA. Safety and efficacy of statin therapy. Nat Rev Cardiol. 2018;15(12):757–69. https://doi.org/10.1038/s41569-018-0098-5. PMID: 30375494.
Article CAS PubMed Google Scholar
Alzheimer’s Disease Anti-inflammatory Prevention Trial Research Group. Results of a follow-up study to the randomized Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT). Alzheimers Dement. 2013;9(6):714–23. https://doi.org/10.1016/j.jalz.2012.11.012. Epub 2013 Apr 3. PMID: 23562431; PMCID: PMC3823756.
Article Google Scholar
Ancelin ML, Carrière I, Barberger-Gateau P, et al. Lipid lowering agents, cognitive decline, and dementia: the three-city study. J Alzheimers Dis. 2012;30(3):629–37. https://doi.org/10.3233/JAD-2012-120064.
Article CAS PubMed PubMed Central Google Scholar
Anstey KJ, Lipnicki DM, Low LF. Cholesterol as a risk factor for dementia and cognitive decline: a systematic review of prospective studies with meta-analysis. Am J Geriatr Psychiatry. 2008;16(5):343–54. https://doi.org/10.1097/JGP.0b013e31816b72d4. PMID: 18448847.
Article PubMed Google Scholar
Anstey KJ, Ashby-Mitchell K, Peters R. Updating the evidence on the association between serum cholesterol and risk of late-life dementia: review and meta-analysis. J Alzheimers Dis. 2017;56(1):215–28. https://doi.org/10.3233/JAD-160826. PMID: 27911314; PMCID: PMC5240556.
Article PubMed PubMed Central Google Scholar
Arrazola Sastre A, Luque Montoro M, Gálvez-Martín P, et al. Small GTPases of the Ras and Rho Families Switch on/off Signaling Pathways in Neurodegenerative Diseases. Int J Mol Sci. 2020;21(17):6312. Published 2020 Aug 31. https://doi.org/10.3390/ijms21176312.
Article CAS PubMed Central Google Scholar
Arvanitakis Z, Schneider JA, Wilson RS, Bienias JL, Kelly JF, Evans DA, Bennett DA. Statins, incident Alzheimer disease, change in cognitive function, and neuropathology. Neurology. 2008;70(19 Pt 2):1795–802. https://doi.org/10.1212/01.wnl.0000288181.00826.63. Epub 2008 Jan 16. PMID: 18199831.
Article CAS PubMed Google Scholar
Barone E, Di Domenico F, Butterfield DA. Statins more than cholesterol lowering agents in Alzheimer disease: their pleiotropic functions as potential therapeutic targets. Biochem Pharmacol. 2014;88(4):605–16. https://doi.org/10.1016/j.bcp.2013.10.030. Epub 2013 Nov 11. PMID: 24231510; PMCID: PMC3972306.
Article CAS PubMed Google Scholar
Bathina S, Das UN. Brain-derived neurotrophic factor and its clinical implications. Arch Med Sci. 2015;11(6):1164–78. https://doi.org/10.5114/aoms.2015.56342.
Article CAS PubMed PubMed Central Google Scholar
Bettermann K, Arnold AM, Williamson J, Rapp S, Sink K, Toole JF, Carlson MC, Yasar S, Dekosky S, Burke GL. Statins, risk of dementia, and cognitive function: secondary analysis of the ginkgo evaluation of memory study. J Stroke Cerebrovasc Dis. 2012;21(6):436–44. https://doi.org/10.1016/j.jstrokecerebrovasdis.2010.11.002. Epub 2011 Jan 14. PMID: 21236699; PMCID: PMC3140577.
Article PubMed Google Scholar
Birks J, Grimley EJ. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev. 2007;2:CD003120. https://doi.org/10.1002/14651858.CD003120.pub2. Update in: Cochrane Database Syst Rev. 2009;(1):CD003120. PMID: 17443523.
Article Google Scholar
Bosch J, Yusuf S, Pogue J, Sleight P, Lonn E, Rangoonwala B, Davies R, Ostergren J, Probstfield J, HOPE Investigators. Heart outcomes prevention evaluation. Use of ramipril in preventing stroke: double blind randomised trial. BMJ. 2002;324(7339):699–702. https://doi.org/10.1136/bmj.324.7339.699. PMID: 11909785; PMCID: PMC99052.
Article CAS PubMed PubMed Central Google Scholar
Budson AE, Solomon PR, Budson AE (2016) Memory loss, Alzheimer’s disease, and dementia: a practical guide for clinicians. https://www.clinicalkey.com/dura/browse/bookChapter/3-s2.0-C20130000011
Chen X, Guo C, Kong J. Oxidative stress in neurodegenerative diseases. Neural Regen Res. 2012;7(5):376–85. https://doi.org/10.3969/j.issn.1673-5374.2012.05.009.
Article CAS PubMed PubMed Central Google Scholar
Cholesterol Treatment Trialists’ (CTT) Collaborators, Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A, Collins R, Baigent C. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581–90. https://doi.org/10.1016/S0140-6736(12)60367-5. Epub 2012 May 17. PMID: 22607822; PMCID: PMC3437972.
Article CAS Google Scholar
Chu CS, Tseng PT, Stubbs B, Chen TY, Tang CH, Li DJ, Yang WC, Chen YW, Wu CK, Veronese N, Carvalho AF, Fernandes BS, Herrmann N, Lin PY. Use of statins and the risk of dementia and mild cognitive impairment: a systematic review and meta-analysis. Sci Rep. 2018;8(1):5804. https://doi.org/10.1038/s41598-018-24248-8. PMID: 29643479; PMCID: PMC5895617.
Article CAS PubMed PubMed Central Google Scholar
De-Paula VJ, Radanovic M, Diniz BS, Forlenza OV. Alzheimer’s disease. Subcell Biochem. 2012;65:329–52. https://doi.org/10.1007/978-94-007-5416-4_14. PMID: 23225010.
Article CAS PubMed Google Scholar
Emeriau JP, Lehert P, Mosnier M. Efficacy of naftidrofuryl in patients with vascular or mixed dementia: results of a multicenter, double-blind trial. Clin Ther. 2000;22(7):834–44. https://doi.org/10.1016/S0149-2918(00)80056-9. PMID: 10945510.
Article CAS PubMed Google Scholar
Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res. 1992;33(11):1569–82. PMID: 1464741.
Article CAS Google Scholar
Farooq MU, Min J, Goshgarian C, Gorelick PB. Pharmacotherapy for vascular cognitive impairment. CNS Drugs. 2017;31(9):759–76. https://doi.org/10.1007/s40263-017-0459-3. PMID: 28786085.
Article CAS PubMed Google Scholar
Fioravanti M, Flicker L. Nicergoline for dementia and other age associated forms of cognitive impairment. Cochrane Database Syst Rev. 2001;4:Art. No.: CD003159. https://doi.org/10.1002/14651858.CD003159.
Article Google Scholar
Fioravanti M, Nakashima T, Xu J, Garg A. A systematic review and meta-analysis assessing adverse event profile and tolerability of nicergoline. BMJ Open. 2014;4(7):e005090. https://doi.org/10.1136/bmjopen-2014-005090. PMID: 25079927; PMCID: PMC4120366.
Article PubMed PubMed Central Google Scholar
Forette F, Seux ML, Staessen JA, Thijs L, Birkenhäger WH, Babarskiene MR, Babeanu S, Bossini A, Gil-Extremera B, Girerd X, Laks T, Lilov E, Moisseyev V, Tuomilehto J, Vanhanen H, Webster J, Yodfat Y, Fagard R. Prevention of dementia in randomised double-blind placebo-controlled systolic hypertension in Europe (Syst-Eur) trial. Lancet. 1998;352(9137):1347–51. https://doi.org/10.1016/s0140-6736(98)03086-4. PMID: 9802273.
Article CAS PubMed Google Scholar
Fracassi A, Marangoni M, Rosso P, et al. Statins and the brain: more than lipid lowering agents? Curr Neuropharmacol. 2019;17(1):59–83. https://doi.org/10.2174/1570159X15666170703101816.
Article CAS PubMed PubMed Central Google Scholar
Geifman N, Brinton RD, Kennedy RE, Schneider LS, Butte AJ. Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer’s disease. Alzheimers Res Ther. 2017;9:10. https://doi.org/10.1186/s13195-017-0237-y.
Article CAS PubMed PubMed Central Google Scholar
Glynn RJ, Schneeweiss S, Wang PS, Levin R, Avorn J. Selective prescribing led to overestimation of the benefits of lipid-lowering drugs. J Clin Epidemiol. 2006;59:819–28. https://doi.org/10.1016/j.jclinepi.2005.12.012.
Article PubMed Google Scholar
Golomb BA, McGraw JJ, Evans MA, Dimsdale JE. Physician response to patient reports of adverse drug effects: implications for patient-targeted adverse effect surveillance. Drug Saf. 2007;30(8):669–75. https://doi.org/10.2165/00002018-200730080-00003. PMID: 17696579.
Article PubMed Google Scholar
Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22.
Article Google Scholar
Ihl R, Frölich L, Winblad B, Schneider L, Burns A, Möller HJ, WFSBP Task Force on Treatment Guidelines for Alzheimer’s Disease and other Dementias. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of Alzheimer’s disease and other dementias. World J Biol Psychiatry. 2011;12(1):2–32. https://doi.org/10.3109/15622975.2010.538083. PMID: 21288069.
Article PubMed Google Scholar
Im JJ, Jeong HS, Park JS, Yang Y, Na SH, Oh JK, Chung YA, Song IU. Changes in Regional Cerebral Perfusion after Nicergoline Treatment in Early Alzheimer's Disease: A Pilot Study. Dement Neurocogn Disord. 2017;16(4):104–109. https://doi.org/10.12779/dnd.2017.16.4.104. Epub 2017 Dec 31. PMID: 30906380; PMCID: PMC6428003.
Imbimbo BP, Solfrizzi V, Panza F. Are NSAIDs useful to treat Alzheimer’s disease or mild cognitive impairment? Front Aging Neurosci. 2010;2:19. Published 2010 May 21. https://doi.org/10.3389/fnagi.2010.00019.
Article CAS PubMed PubMed Central Google Scholar
Jeong A, Suazo KF, Wood WG, Distefano MD, Li L. Isoprenoids and protein prenylation: implications in the pathogenesis and therapeutic intervention of Alzheimer’s disease. Crit Rev Biochem Mol Biol. 2018;53(3):279–310. https://doi.org/10.1080/10409238.2018.1458070.
Article PubMed PubMed Central Google Scholar
Jooyeon J. Im, Hyeonseok S. Jeong, Jong-Sik Park, YoungSoon Yang, Seung-Hee Na, Jin Kyoung Oh, Yong-An Chung, In-Uk Song, (2017) Changes in Regional Cerebral Perfusion after Nicergoline Treatment in Early Alzheimer’s Disease: A Pilot Study. Dementia and Neurocognitive Disorders 2017;16(4):104
Google Scholar
Kandiah N, Ong PA, Yuda T, Ng LL, Mamun K, Merchant RA, et al. Treatment of dementia and mild cognitive impairment with or without cerebrovascular disease: expert consensus on the use of Ginkgo biloba extract, EGb 761((R)). CNS Neurosci Ther. 2019;25(2):288–98. [PMID: 30648358].
Article Google Scholar
Kapur NK, Musunuru K. Clinical efficacy and safety of statins in managing cardiovascular risk. Vasc Health Risk Manag. 2008;4(2):341–53.
Article CAS Google Scholar
Klafki HW, Staufenbiel M, Kornhuber J, Wiltfang J. Therapeutic approaches to Alzheimer’s disease. Brain. 2006;129(Pt 11):2840–55. https://doi.org/10.1093/brain/awl280. Epub 2006 Oct 3. PMID: 17018549.
Article PubMed Google Scholar
Kurata T, Miyazaki K, Kozuki M, Morimoto N, Ohta Y, Ikeda Y, Abe K. Atorvastatin and pitavastatin reduce senile plaques and inflammatory responses in a mouse model of Alzheimer’s disease. Neurol Res. 2012;34(6):601–10. https://doi.org/10.1179/1743132812Y.0000000054. Epub 2012 Jun 22. PMID: 22732109.
Article CAS PubMed Google Scholar
Kurinami H, Sato N, Shinohara M, Takeuchi D, Takeda S, Shimamura M, et al. Prevention of amyloid β-induced memory impairment by fluvastatin, associated with the decrease in amyloid β accumulation and oxidative stress in amyloid β injection mouse model. Int J Mol Med. 2008;21(5):531–7.
CAS PubMed Google Scholar
Kyriakos G, Quiles-SÁnchez LV, Diamantis E, et al. Lipid-lowering drugs and neurocognitive function: a systematic review. In Vivo. 2020;34(6):3109–14. https://doi.org/10.21873/invivo.12144.
Article CAS PubMed PubMed Central Google Scholar
Levi Marpillat N, Macquin-Mavier I, Tropeano AI, Bachoud-Levi AC, Maison P. Antihypertensive classes, cognitive decline and incidence of dementia: a network meta-analysis. J Hypertens. 2013;31(6):1073–82. https://doi.org/10.1097/HJH.0b013e3283603f53. PMID: 23552124.
Article CAS PubMed Google Scholar
Li G, et al. Age-varying association between statin use and incident Alzheimer’s disease. J Am Geriatr Soc. 2010;58:1311–7. https://doi.org/10.1111/j.1532-5415.2010.02906.x.
Article PubMed PubMed Central Google Scholar
Liu JX, Pinnock SB, Herbert J. Novel control by the CA3 region of the hippocampus on neurogenesis in the dentate gyrus of the adult rat. PLoS One. 2011;6(3):e17562. https://doi.org/10.1371/journal.pone.0017562. PMID: 21464973; PMCID: PMC3060811.
Article CAS PubMed PubMed Central Google Scholar
Lu D, Qu C, Goussev A, Jiang H, Lu C, Schallert T, Mahmood A, Chen J, Li Y, Chopp M. Statins increase neurogenesis in the dentate gyrus, reduce delayed neuronal death in the hippocampal CA3 region, and improve spatial learning in rat after traumatic brain injury. J Neurotrauma. 2007;24(7):1132–46. https://doi.org/10.1089/neu.2007.0288. PMID: 17610353; PMCID: PMC1971229.
Article PubMed PubMed Central Google Scholar
Lu D, Song H, Hao Z, Wu T, McCleery J. Naftidrofuryl for dementia. Cochrane Database Syst Rev. 2011;12:CD002955. https://doi.org/10.1002/14651858.CD002955.pub4. PMID: 22161372.
Article Google Scholar
Mans RA, Chowdhury N, Cao D, McMahon LL, Li L. Simvastatin enhances hippocampal long-term potentiation in C57BL/6 mice. Neuroscience. 2010;166(2):435–44. https://doi.org/10.1016/j.neuroscience.2009.12.062.
Article CAS PubMed Google Scholar
McArthur RA, Carfagna N, Banfi L, Cavanus S, Cervini MA, Fariello R, Post C. Effects of Nicergoline on age-related decrements in radial maze performance and acetylcholine levels. Brain Res Bull. 1997;43(3):305–11. https://doi.org/10.1016/s0361-9230(97)00010-5.
Article CAS PubMed Google Scholar
McGuinness B, Todd S, Passmore P, Bullock R. Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. Cochrane Database Syst Rev. 2009:CD004034.
Google Scholar
McGuinness B, Craig D, Bullock R, Passmore P. Statins for the prevention of dementia. Cochrane Database Syst Rev. 2016;1:CD003160. https://doi.org/10.1002/14651858.CD003160.pub3. PMID: 26727124.
Article Google Scholar
Müller WE, Eckert A, Eckert GP, Fink H, Friedland K, Gauthier S, Hoerr R, Ihl R, Kasper S, Möller HJ. Therapeutic efficacy of the Ginkgo special extract EGb761® within the framework of the mitochondrial cascade hypothesis of Alzheimer’s disease. World J Biol Psychiatry. 2019;20(3):173–89. https://doi.org/10.1080/15622975.2017.1308552. Epub 2017 May 2. PMID: 28460580.
Article PubMed Google Scholar
Muñoz-Jiménez M, Zaarkti A, García-Arnés JA, García-Casares N. Antidiabetic drugs in Alzheimer’s disease and mild cognitive impairment: a systematic review. Dement Geriatr Cogn Disord. 2020;20:1–12. https://doi.org/10.1159/000510677. Epub ahead of print. PMID: 33080602.
Article CAS Google Scholar
Ott BR, Daiello LA, Dahabreh IJ, Springate BA, Bixby K, Murali M, Trikalinos TA. Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials. J Gen Intern Med. 2015;30(3):348–58. https://doi.org/10.1007/s11606-014-3115-3. Epub 2015 Jan 10. PMID: 25575908; PMCID: PMC4351273.
Article PubMed PubMed Central Google Scholar
Owen L, Sunram-Lea SI. Metabolic agents that enhance ATP can improve cognitive functioning: a review of the evidence for glucose, oxygen, pyruvate, creatine, and L-carnitine. Nutrients. 2011;3(8):735–55. https://doi.org/10.3390/nu3080735.
Article CAS PubMed PubMed Central Google Scholar
Pahan K. Lipid-lowering drugs. Cell Mol Life Sci. 2006;63(10):1165–78.
Article CAS Google Scholar
Picciotto MR, Higley MJ, Mineur YS. Acetylcholine as a neuromodulator: cholinergic signaling shapes nervous system function and behavior. Neuron. 2012;76(1):116–29. https://doi.org/10.1016/j.neuron.2012.08.036.
Article CAS PubMed PubMed Central Google Scholar
Poly TN, Islam MM, Walther BA, Yang HC, Wu CC, Lin MC, Li YC. Association between use of statin and risk of dementia: a meta-analysis of observational studies. Neuroepidemiology. 2020;54(3):214–26. https://doi.org/10.1159/000503105. Epub 2019 Oct 1. PMID: 31574510.
Article PubMed Google Scholar
Richardson K, Schoen M, French B, Umscheid CA, Mitchell MD, Arnold SE, et al. Statins and cognitive function: a systematic review. Ann Intern Med. 2013;159:688–97. https://doi.org/10.7326/0003-4819-159-10-201311190-00007.
Article PubMed Google Scholar
Robin NC, Agoston Z, Biechele TL, James RG, Berndt JD, Moon RT. Simvastatin promotes adult hippocampal neurogenesis by enhancing Wnt/β-catenin signaling. Stem Cell Rep. 2013;2(1):9–17. Published 2013 Dec 26. https://doi.org/10.1016/j.stemcr.2013.11.002.
Article CAS Google Scholar
Rockwood K, et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol. 2002;59:223–7. https://doi.org/10.1001/archneur.59.2.223.
Article PubMed Google Scholar
Roy A, Jana M, Corbett GT, et al. Regulation of cyclic AMP response element binding and hippocampal plasticity-related genes by peroxisome proliferator-activated receptor α. Cell Rep. 2013;4(4):724–37. https://doi.org/10.1016/j.celrep.2013.07.028.
Article CAS PubMed PubMed Central Google Scholar
Saeedi Saravi SS, Saeedi Saravi SS, Arefidoust A, Dehpour AR. The beneficial effects of HMG-CoA reductase inhibitors in the processes of neurodegeneration. Metab Brain Dis. 2017;32(4):949–65. https://doi.org/10.1007/s11011-017-0021-5. Epub 2017 Jun 3. PMID: 28578514.
Article CAS PubMed Google Scholar
Saletu B, Garg A, Shoeb A. Safety of nicergoline as an agent for management of cognitive function disorders. Biomed Res Int. 2014;2014:610103. https://doi.org/10.1155/2014/610103. Epub 2014 Aug 28. PMID: 25243157; PMCID: PMC4163411.
Article CAS PubMed PubMed Central Google Scholar
Salins P, Shawesh S, He Y, Dibrov A, Kashour T, Arthur G, Amara F. Lovastatin protects human neurons against Abeta-induced toxicity and causes activation of beta-catenin-TCF/LEF signaling. Neurosci Lett. 2007;412(3):211–6. https://doi.org/10.1016/j.neulet.2006.07.045. Epub 2007 Jan 17. PMID: 17234346.
Article CAS PubMed Google Scholar
Samaras K, Makkar SR, Crawford JD, Kochan NA, Slavin MJ, Wen W, Trollor JN, Brodaty H, Sachdev PS. Effects of statins on memory, cognition, and brain volume in the elderly. J Am Coll Cardiol. 2019;74(21):2554–68. https://doi.org/10.1016/j.jacc.2019.09.041. PMID: 31753200.
Article CAS PubMed Google Scholar
Savolainen-Peltonen H, Rahkola-Soisalo P, Hoti F, et al. Use of postmenopausal hormone therapy and risk of Alzheimer’s disease in Finland: nationwide case-control study. BMJ. 2019;364:l665. Published 2019 Mar 6. https://doi.org/10.1136/bmj.l665.
Article PubMed PubMed Central Google Scholar
Schultz BG, Patten DK, Berlau DJ. The role of statins in both cognitive impairment and protection against dementia: a tale of two mechanisms. Transl Neurodegener. 2018;7:5. https://doi.org/10.1186/s40035-018-0110-3. PMID: 29507718; PMCID: PMC5830056.
Article CAS PubMed PubMed Central Google Scholar
Shah NP, Swiger KJ, Martin SS. Impact on cognitive function-are all statins the same? Curr Atheroscler Rep. 2015;17(1):466. https://doi.org/10.1007/s11883-014-0466-5. PMID: 25398642.
Article CAS PubMed Google Scholar
Shepardson NE, Shankar GM, Selkoe DJ. Cholesterol level and statin use in Alzheimer disease: II. Review of human trials and recommendations. Arch Neurol. 2011;68(11):1385–92. https://doi.org/10.1001/archneurol.2011.242.
Article PubMed PubMed Central Google Scholar
Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, Hendrix SL, Jones BN 3rd, Assaf AR, Jackson RD, Kotchen JM, Wassertheil-Smoller S, Wactawski-Wende J, WHIMS Investigators. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women’s Health Initiative memory study: a randomized controlled trial. JAMA. 2003;289(20):2651–62. https://doi.org/10.1001/jama.289.20.2651. PMID: 12771112.
Article CAS PubMed Google Scholar
Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Lane DS, Fillit H, Stefanick ML, Hendrix SL, Lewis CE, Masaki K, Coker LH, Women’s Health Initiative Memory Study. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women’s Health Initiative memory study. JAMA. 2004;291(24):2947–58. https://doi.org/10.1001/jama.291.24.2947. PMID: 15213206.
Article CAS PubMed Google Scholar
Song Y, Nie H, Xu Y, Zhang L, Wu Y. Association of statin use with risk of dementia: a meta-analysis of prospective cohort studies. Geriatr Gerontol. 2013;13:817–24.
Google Scholar
Sparks DL, et al. Statin therapy in Alzheimer’s disease. Acta Neurol Scand Suppl. 2006;185:78–86. https://doi.org/10.1111/j.1600-0404.2006.00689.x.
Article CAS PubMed Google Scholar
Swiger KJ, Manalac RJ, Blumenthal RS, Blaha MJ, Martin SS. Statins and cognition: a systematic review and meta-analysis of short- and long-term cognitive effects. Mayo Clin Proc. 2013;88:1213–21. https://doi.org/10.1016/j.mayocp.2013.07.013.
Article CAS PubMed Google Scholar
Tong XK, Nicolakakis N, Fernandes P, Ongali B, Brouillette J, Quirion R, et al. Simvastatin improves cerebrovascular function and counters soluble amyloid-beta, inflammation and oxidative stress in aged APP mice. Neurobiol Dis. 2009;35(3):406–14.
Article CAS Google Scholar
Tong XK, Lecrux C, Rosa-Neto P, Hamel E. Age-dependent rescue by simvastatin of Alzheimer’s disease cerebrovascular and memory deficits. J Neurosci. 2012;32(14):4705–15.
Article CAS Google Scholar
Torrandell-Haro G, Branigan GL, Vitali F, Geifman N, Zissimopoulos JM, Brinton RD. Statin therapy and risk of Alzheimer’s and age-related neurodegenerative diseases. Alzheimers Dement. 2020;6:e12108. https://doi.org/10.1002/trc2.12108.
Article Google Scholar
Trompet S, van Vliet P, de Craen AJ, Jolles J, Buckley BM, Murphy MB, Ford I, Macfarlane PW, Sattar N, Packard CJ, Stott DJ, Shepherd J, Bollen EL, Blauw GJ, Jukema JW, Westendorp RG. Pravastatin and cognitive function in the elderly. Results of the PROSPER study. J Neurol. 2010;257(1):85–90. https://doi.org/10.1007/s00415-009-5271-7. Epub 2009 Aug 4. PMID: 19653027.
Article CAS PubMed Google Scholar
Tseng CH. Rosiglitazone has a neutral effect on the risk of dementia in type 2 diabetes patients. Aging (Albany NY). 2019;11(9):2724–34. https://doi.org/10.18632/aging.101944.
Article CAS Google Scholar
Tzourio C, Anderson C, Chapman N, Woodward M, Neal B, MacMahon S, Chalmers J; PROGRESS Collaborative Group. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med. 2003;163(9):1069–75. https://doi.org/10.1001/archinte.163.9.1069. PMID: 12742805.
Walker KA, Power MC, Gottesman RF. Defining the relationship between hypertension, cognitive decline, and dementia: a review. Curr Hypertens Rep. 2017;19(3):24. https://doi.org/10.1007/s11906-017-0724-3.
Article PubMed PubMed Central Google Scholar
Wieland LS, Feinberg TM, Ludeman E, Prasad NK, Amri H. Ginkgo biloba for cognitive impairment and dementia (Protocol). Cochrane Database Syst Rev. 2020;7:Art. No.: CD013661. https://doi.org/10.1002/14651858.CD013661.
Article Google Scholar
Winblad B, Fioravanti M, Dolezal T, Logina I, Milanov IG, Popescu DC, Solomon A. Therapeutic use of nicergoline. Clin Drug Investig. 2008;28(9):533–52. https://doi.org/10.2165/00044011-200828090-00001. PMID: 18666801.
Article CAS PubMed Google Scholar
Wolozin B, Manger J, Bryant R, Cordy J, Green RC, McKee A. Re-assessing the relationship between cholesterol, statins and Alzheimer’s disease. Acta Neurol Scand Suppl. 2006;185:63–70. https://doi.org/10.1111/j.1600-0404.2006.00687.x. PMID: 16866913.
Article CAS PubMed Google Scholar

Download references

Author information

Authors and Affiliations

Department of Neurology, Antalya Training and Research Hospital, Antalya, Turkey
Aylin Yaman
Independent Scholar, Family Physician, Antalya, Turkey
Hakan Yaman

Authors

Aylin Yaman
View author publications
You can also search for this author in PubMed Google Scholar
Hakan Yaman
View author publications
You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

Dept Psychiatry , Psychosomatics & Psychotherapy, University of Würzburg, Medical School Clinical Neurochemistry, Würzburg, Germany
Peter Riederer
Inst für Psychologische Medizin, Haag, Bayern, Germany
Gerd Laux
Fujita Health University School Medicine, Toyoake, Aichi, Japan
Toshiharu Nagatsu
Center Translational Res Neurol Diseases, Dalian Med Uni Shanghai Inst Health Sc Center Translational Res Neurol Diseases, Dalian, China
Weidong Le
Würzburg, Bayern, Germany
Christian Riederer

Section Editor information

MTA-SZTE, Neuroscience Research Group, Szeged, Hungary
László Vécsei
Department of Neurology, Interdisciplinary Excellence Centre, Faculty of Medicine, University of Szeged, Szeged, Hungary
László Vécsei

Rights and permissions

Reprints and permissions

Copyright information

About this entry

Cite this entry

Yaman, A., Yaman, H. (2021). Complementary Medications (Statins, Nicergoline, Naftidrofuryl) in Dementia. In: Riederer, P., Laux, G., Nagatsu, T., Le, W., Riederer, C. (eds) NeuroPsychopharmacotherapy. Springer, Cham. https://doi.org/10.1007/978-3-319-56015-1_422-1

Download citation

DOI: https://doi.org/10.1007/978-3-319-56015-1_422-1
Received: 10 March 2021
Accepted: 23 March 2021
Published: 01 June 2021
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-56015-1
Online ISBN: 978-3-319-56015-1
eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics